A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...

NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and ...

University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...

A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...

Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB ...

Damien Chua, PhD student; Liu Yu Xuan, Research Associate; Joseph Kim, PhD student; Cheng Hong Sheng, Senior Research Fellow; and ...

Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.